These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 16280340)
1. The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? Bushe C; Paton C J Psychopharmacol; 2005 Nov; 19(6 Suppl):76-83. PubMed ID: 16280340 [TBL] [Abstract][Full Text] [Related]
2. Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy. Huang TL; Lu CY Chang Gung Med J; 2007; 30(1):26-32. PubMed ID: 17477026 [TBL] [Abstract][Full Text] [Related]
3. Effect of antipsychotic medications on glucose and lipid levels. Chaggar PS; Shaw SM; Williams SG J Clin Pharmacol; 2011 May; 51(5):631-8. PubMed ID: 20410451 [TBL] [Abstract][Full Text] [Related]
4. [Metabolic risk during antipsychotic treatment in patients with schizophrenia]. Rzewuska M Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977 [TBL] [Abstract][Full Text] [Related]
5. LDL cholesterol estimation using the Anandaraja's and Friedewald's formulas in schizophrenic patients treated with antipsychotic drugs. Paz E; Hermida J; Bouzas L; Brenlla J; Tutor JC Clin Biochem; 2008 Aug; 41(12):1002-7. PubMed ID: 18474233 [TBL] [Abstract][Full Text] [Related]
6. Use and safety of antipsychotic drugs during pregnancy. Einarson A; Boskovic R J Psychiatr Pract; 2009 May; 15(3):183-92. PubMed ID: 19461391 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Hanssens L; De Hert M; Kalnicka D; van Winkel R; Wampers M; Van Eyck D; Scheen A; Peuskens J Int Clin Psychopharmacol; 2007 Jan; 22(1):43-9. PubMed ID: 17159459 [TBL] [Abstract][Full Text] [Related]
8. Review: Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. Chan J; Sweeting M J Psychopharmacol; 2007 Aug; 21(6):657-64. PubMed ID: 17092976 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216 [TBL] [Abstract][Full Text] [Related]
10. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Kaddurah-Daouk R; McEvoy J; Baillie RA; Lee D; Yao JK; Doraiswamy PM; Krishnan KR Mol Psychiatry; 2007 Oct; 12(10):934-45. PubMed ID: 17440431 [TBL] [Abstract][Full Text] [Related]
11. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Stahl SM; Mignon L; Meyer JM Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394 [TBL] [Abstract][Full Text] [Related]
12. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270 [TBL] [Abstract][Full Text] [Related]
13. How to manage in current treatment of schizophrenic patients. Loga S Psychiatr Danub; 2007 Dec; 19(4):359-61. PubMed ID: 18000489 [TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810 [TBL] [Abstract][Full Text] [Related]
15. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. Weiden PJ J Clin Psychiatry; 2007; 68 Suppl 4():34-9. PubMed ID: 17539698 [TBL] [Abstract][Full Text] [Related]
16. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548 [TBL] [Abstract][Full Text] [Related]
17. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718 [TBL] [Abstract][Full Text] [Related]
18. The metabolic syndrome and schizophrenia. Meyer JM; Stahl SM Acta Psychiatr Scand; 2009 Jan; 119(1):4-14. PubMed ID: 19133915 [TBL] [Abstract][Full Text] [Related]
19. The association between dyslipidaemia and types of antipsychotic medications among patients with chronic schizophrenia. Ruzanna ZZ; Ong LY; Cheah YC; Fairuz A; Marhani M Med J Malaysia; 2012 Feb; 67(1):39-44. PubMed ID: 22582547 [TBL] [Abstract][Full Text] [Related]
20. Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment. Zhai D; Cui T; Xu Y; Feng Y; Wang X; Yang Y; Li S; Zhou D; Dong G; Zhao Y; Yang Y; Zhang R Schizophr Res; 2017 Jan; 179():41-49. PubMed ID: 27613506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]